StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics cash

Cash and short-term investments held at the end of each period.

Axsome Therapeutics's cash was $319.85M at Jun 30, 2026. For fiscal 2025 it was $322.93M, up 2.4% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $386.19M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$322.93M+2.4%
FY2024Dec 31, 2024$315.35M-18.3%
FY2023Dec 31, 2023$386.19M+92.3%
FY2022Dec 31, 2022$200.84M+132.3%
FY2021Dec 31, 2021$86.47M-53.0%
FY2020Dec 31, 2020$183.88M-16.4%
FY2019Dec 31, 2019$219.97M+1474.7%
FY2018Dec 31, 2018$13.97M-58.9%
FY2017Dec 31, 2017$34.02M-7.1%
FY2016Dec 31, 2016$36.62M-23.8%
FY2015Dec 31, 2015$48.04M+1735.0%
FY2014Dec 31, 2014$2.62M+25.4%
FY2013Dec 31, 2013$2.09M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$319.85M+5.6%
Q1 FY2026Mar 31, 2026$305.11M+1.4%
Q4 FY2025Dec 31, 2025$322.93M+2.4%
Q3 FY2025Sep 30, 2025$325.27M-0.6%
Q2 FY2025Jun 30, 2025$303.02M-4.0%
Q1 FY2025Mar 31, 2025$300.91M-9.2%
Q4 FY2024Dec 31, 2024$315.35M-18.3%
Q3 FY2024Sep 30, 2024$327.34M-21.4%
Q2 FY2024Jun 30, 2024$315.66M-27.8%
Q1 FY2024Mar 31, 2024$331.44M+34.5%
Q4 FY2023Dec 31, 2023$386.19M+92.3%
Q3 FY2023Sep 30, 2023$416.56M+83.1%
Q2 FY2023Jun 30, 2023$437.11M+495.6%
Q1 FY2023Mar 31, 2023$246.52M+191.0%
Q4 FY2022Dec 31, 2022$200.84M+132.3%
Q3 FY2022Sep 30, 2022$227.52M+98.5%
Q2 FY2022Jun 30, 2022$73.39M-48.0%
Q1 FY2022Mar 31, 2022$84.71M-48.6%
Q4 FY2021Dec 31, 2021$86.47M-53.0%
Q3 FY2021Sep 30, 2021$114.62M-43.4%
Q2 FY2021Jun 30, 2021$141.22M-25.9%
Q1 FY2021Mar 31, 2021$164.66M-16.5%
Q4 FY2020Dec 31, 2020$183.88M-16.4%
Q3 FY2020Sep 30, 2020$202.36M+363.7%
Q2 FY2020Jun 30, 2020$190.68M+254.7%
Q1 FY2020Mar 31, 2020$197.31M+362.9%
Q4 FY2019Dec 31, 2019$219.97M+1474.7%
Q3 FY2019Sep 30, 2019$43.64M+186.7%
Q2 FY2019Jun 30, 2019$53.75M+164.1%
Q1 FY2019Mar 31, 2019$42.62M+60.0%
Q4 FY2018Dec 31, 2018$13.97M-58.9%
Q3 FY2018Sep 30, 2018$15.22M-51.9%
Q2 FY2018Jun 30, 2018$20.35M-46.4%
Q1 FY2018Mar 31, 2018$26.63M-40.8%
Q4 FY2017Dec 31, 2017$34.02M-7.1%
Q3 FY2017Sep 30, 2017$31.67M-6.5%
Q2 FY2017Jun 30, 2017$37.99M–
Q1 FY2017Mar 31, 2017$45.02M–
Q4 FY2016Dec 31, 2016$36.62M–
Q3 FY2016Sep 30, 2016$33.89M–

More Axsome Therapeutics figures

See a number that looks wrong?